Physician profile
Dipesh Deray
NPI 1427382407
$10,190.65
in general payments reported to CMS, 2019-2025
52 companies · $2,136 in 2025
The $2,136 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $1,159 · 2021: $1,471 · 2022: $410 · 2023: $1,852 · 2024: $1,726 · 2025: $2,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,697 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,696.69 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,356.39 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $987.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $812.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $803.92 | 2019-2025 | |
| Amgen INC. | $551.21 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $503.76 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $449.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $387.67 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $361.89 | 2019-2024 | Watchman Flx |
| Axsome Therapeutics, INC. | $351.72 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.44 | 2019-2025 | Jardiance |
| Abbvie INC. | $316.99 | 2021-2025 | Vraylar |
| Exact Sciences Corporation | $303.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insmed, INC. | $213.06 | 2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $187.65 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipesh Deray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.